Jonathan Kahn
Biographic Data
| ID | 3660223 |
|---|---|
| NAME | Jonathan Kahn |
| GIVEN NAMES | Jonathan |
| FAMILY NAME | Kahn |
| SIGNATURE | KAHN J |
| AFFILIATIONS | Hamline University |
| VERIFIED | No |
| TOTAL WORKS | 11 |
| TOTAL CITATIONS | 48 |
| AUTHOR COUNT | 11 |
| EDITOR COUNT | 0 |
| FIRST PUBLICATION YEAR | 1993 |
| LATEST PUBLICATION YEAR | 2017 |
| H-INDEX | 4 |
Anthony Ryan Hatch, Blood Sugar: Racial Pharmacology and Food Justice in Black America
It has now been just over 50 years since Martin Luther King, Jr.’s ringing pronouncement that ‘Of all the forms of inequality, injustice in health care is the most shocking and inhumane’.1 The concern for racial disparities in heath and health care has gained increasing traction in academic and policy circles since the publication of the Institute of Medicine’s Unequal Treatment: Confronting Racial and Ethnic Disparities in Healthcare.2 Yet, of c…
When are you from?' Time, space, and capital in the molecular reinscription of race
People's Science: Bodies and Rights on the Stem Cell Frontier
Exploiting Race in Drug Development: BiDil's Interim Model of Pharmacogenomics
This paper explores events surrounding the US Food and Drug Administration's formal approval of the heart failure drug BiDil in 2005. BiDil is the first drug ever to be approved with a race-specific indication, in this case to treat heart failure in 'self-identified black patients'. BiDil has been cast by many as a step toward the promised land of individualized pharmacogenomic therapies. This paper argues, however, that when examined in context,…
The Science and Business of Genetic Ancestry Testing
Commercially available tests of genetic ancestry have significant scientific limitations, but are serious matters for many test-takers.
Genes, Race, and Population: Avoiding a Collision of Categories
A wide array of federal mandates have a profound impact on the use of racial and ethnic categories in biomedical research, clinical practice, product development, and health policy. Current discussions over the appropriate use of racial and ethnic categories in biomedical contexts have largely focused on the practices of individual researchers. By contrast, our discussion focuses on relations between the daily practices of biomedical professional…
Perspective: "Ethnic Drugs"
Getting the Numbers Right: Statistical Mischief and Racial Profiling in Heart Failure Research
The claim that blacks die from heart failure at a rate twice that of whites is informing efforts to develop and market the drug BiDil, which is currently undergoing clinical trials to be approved by the FDA as the first drug ever specified to treat African Americans--and only African Americans--for heart failure. The drug and its companion statistic have since come to play prominent roles in debates about so-called "racial profiling" in medicine …
Crisis and Commission Government in Memphis: Elite Rule in a Gilded Age City
Translating out of Time: Public Administration and Its History
Re-Presenting Government and Representing the People: Budget Reform and Citizenship in New York City, 1908-1911
Exploiting Race in Drug Development: BiDil's Interim Model of Pharmacogenomics
This paper explores events surrounding the US Food and Drug Administration's formal approval of the heart failure drug BiDil in 2005. BiDil is the first drug ever to be approved with a race-specific indication, in this case to treat heart failure in 'self-identified black patients'. BiDil has been cast by many as a step toward the promised land of individualized pharmacogenomic therapies. This paper argues, however, that when examined in context,…
Getting the Numbers Right: Statistical Mischief and Racial Profiling in Heart Failure Research
The claim that blacks die from heart failure at a rate twice that of whites is informing efforts to develop and market the drug BiDil, which is currently undergoing clinical trials to be approved by the FDA as the first drug ever specified to treat African Americans--and only African Americans--for heart failure. The drug and its companion statistic have since come to play prominent roles in debates about so-called "racial profiling" in medicine …
Genes, Race, and Population: Avoiding a Collision of Categories
A wide array of federal mandates have a profound impact on the use of racial and ethnic categories in biomedical research, clinical practice, product development, and health policy. Current discussions over the appropriate use of racial and ethnic categories in biomedical contexts have largely focused on the practices of individual researchers. By contrast, our discussion focuses on relations between the daily practices of biomedical professional…
When are you from?' Time, space, and capital in the molecular reinscription of race
Re-Presenting Government and Representing the People: Budget Reform and Citizenship in New York City, 1908-1911
Re-Presenting Government and Representing the People: Budget Reform and Citizenship in New York City, 1908-1911
Crisis and Commission Government in Memphis: Elite Rule in a Gilded Age City
Translating out of Time: Public Administration and Its History
Getting the Numbers Right: Statistical Mischief and Racial Profiling in Heart Failure Research
The claim that blacks die from heart failure at a rate twice that of whites is informing efforts to develop and market the drug BiDil, which is currently undergoing clinical trials to be approved by the FDA as the first drug ever specified to treat African Americans--and only African Americans--for heart failure. The drug and its companion statistic have since come to play prominent roles in debates about so-called "racial profiling" in medicine …
Perspective: "Ethnic Drugs"
Genes, Race, and Population: Avoiding a Collision of Categories
A wide array of federal mandates have a profound impact on the use of racial and ethnic categories in biomedical research, clinical practice, product development, and health policy. Current discussions over the appropriate use of racial and ethnic categories in biomedical contexts have largely focused on the practices of individual researchers. By contrast, our discussion focuses on relations between the daily practices of biomedical professional…
The Science and Business of Genetic Ancestry Testing
Commercially available tests of genetic ancestry have significant scientific limitations, but are serious matters for many test-takers.
Exploiting Race in Drug Development: BiDil's Interim Model of Pharmacogenomics
This paper explores events surrounding the US Food and Drug Administration's formal approval of the heart failure drug BiDil in 2005. BiDil is the first drug ever to be approved with a race-specific indication, in this case to treat heart failure in 'self-identified black patients'. BiDil has been cast by many as a step toward the promised land of individualized pharmacogenomic therapies. This paper argues, however, that when examined in context,…
When are you from?' Time, space, and capital in the molecular reinscription of race
People's Science: Bodies and Rights on the Stem Cell Frontier
Anthony Ryan Hatch, Blood Sugar: Racial Pharmacology and Food Justice in Black America
It has now been just over 50 years since Martin Luther King, Jr.’s ringing pronouncement that ‘Of all the forms of inequality, injustice in health care is the most shocking and inhumane’.1 The concern for racial disparities in heath and health care has gained increasing traction in academic and policy circles since the publication of the Institute of Medicine’s Unequal Treatment: Confronting Racial and Ethnic Disparities in Healthcare.2 Yet, of c…
Political science (6 works) · Sociology (5 works) · Law (4 works) · Computer Science (3 works) · History (3 works) · Race (biology (3 works) · Race, Genetics, and Society (3 works) · BRCA gene mutations in cancer (2 works) · Gender Studies (2 works) · Government (linguistics (2 works)